Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 43 entries
Sorted by: Best Match Show Resources per page
The use of active PET to package rosé wine: Changes of aromatic profile by chemical evolution and by transfers.

Food research international (Ottawa, Ont.)

Dombre C, Rigou P, Chalier P.
PMID: 28412004
Food Res Int. 2015 Aug;74:63-71. doi: 10.1016/j.foodres.2015.04.026. Epub 2015 Apr 22.

Active Polyethylene Terephthalate (PET) bottles containing 1 or 3% of oxygen scavenger (named 1osPET and 3osPET) were used to pack rosé wine. Changes in the aromatic profiles were monitored during 12months and compared to those of a wine packed...

Cite
Dombre C, Rigou P, Chalier P. The use of active PET to package rosé wine: Changes of aromatic profile by chemical evolution and by transfers. Food Res Int. 2015;74:63-71doi: 10.1016/j.foodres.2015.04.026.
Dombre, C., Rigou, P., & Chalier, P. (2015). The use of active PET to package rosé wine: Changes of aromatic profile by chemical evolution and by transfers. Food research international (Ottawa, Ont.), 7463-71. https://doi.org/10.1016/j.foodres.2015.04.026
Dombre, Clara, et al. "The use of active PET to package rosé wine: Changes of aromatic profile by chemical evolution and by transfers." Food research international (Ottawa, Ont.) vol. 74 (2015): 63-71. doi: https://doi.org/10.1016/j.foodres.2015.04.026
Dombre C, Rigou P, Chalier P. The use of active PET to package rosé wine: Changes of aromatic profile by chemical evolution and by transfers. Food Res Int. 2015 Aug;74:63-71. doi: 10.1016/j.foodres.2015.04.026. Epub 2015 Apr 22. PMID: 28412004.
Copy Download .nbib Format: NLM
Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology

Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C.
PMID: 27056999
Ann Oncol. 2016 Sep;27:v69-v82. doi: 10.1093/annonc/mdw025. Epub 2016 Apr 07.

No abstract available.

Cite
Hoelzer D, Bassan R, Dombret H, et al. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v69-v82doi: 10.1093/annonc/mdw025.
Hoelzer, D., Bassan, R., Dombret, H., Fielding, A., Ribera, J. M., Buske, C. (2016). Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology, 27v69-v82. https://doi.org/10.1093/annonc/mdw025
Hoelzer, D, et al. "Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up." Annals of oncology : official journal of the European Society for Medical Oncology vol. 27 (2016): v69-v82. doi: https://doi.org/10.1093/annonc/mdw025
Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27:v69-v82. doi: 10.1093/annonc/mdw025. Epub 2016 Apr 07. PMID: 27056999.
Copy Download .nbib Format: NLM
eC-CLEM: flexible multidimensional registration software for correlative microscopies.

Nature methods

Paul-Gilloteaux P, Heiligenstein X, Belle M, Domart MC, Larijani B, Collinson L, Raposo G, Salamero J.
PMID: 28139674
Nat Methods. 2017 Jan 31;14(2):102-103. doi: 10.1038/nmeth.4170.

No abstract available.

Cite
Paul-Gilloteaux P, Heiligenstein X, Belle M, et al. eC-CLEM: flexible multidimensional registration software for correlative microscopies. Nat Methods. 2017;14(2):102-103doi: 10.1038/nmeth.4170.
Paul-Gilloteaux, P., Heiligenstein, X., Belle, M., Domart, M. C., Larijani, B., Collinson, L., Raposo, G., & Salamero, J. (2017). eC-CLEM: flexible multidimensional registration software for correlative microscopies. Nature methods, 14(2), 102-103. https://doi.org/10.1038/nmeth.4170
Paul-Gilloteaux, Perrine, et al. "eC-CLEM: flexible multidimensional registration software for correlative microscopies." Nature methods vol. 14,2 (2017): 102-103. doi: https://doi.org/10.1038/nmeth.4170
Paul-Gilloteaux P, Heiligenstein X, Belle M, Domart MC, Larijani B, Collinson L, Raposo G, Salamero J. eC-CLEM: flexible multidimensional registration software for correlative microscopies. Nat Methods. 2017 Jan 31;14(2):102-103. doi: 10.1038/nmeth.4170. PMID: 28139674.
Copy Download .nbib Format: NLM
Lipid-dependent and -independent regulation of nuclear envelope disassembly.

Journal of chemical biology

Domart MC, Larijani B.
PMID: 24348875
J Chem Biol. 2012 Dec 18;6(1):3-5. doi: 10.1007/s12154-012-0088-8. eCollection 2012.

No abstract available.

Cite
Domart MC, Larijani B. Lipid-dependent and -independent regulation of nuclear envelope disassembly. J Chem Biol. 2012;6(1):3-5doi: 10.1007/s12154-012-0088-8.
Domart, M. C., & Larijani, B. (2012). Lipid-dependent and -independent regulation of nuclear envelope disassembly. Journal of chemical biology, 6(1), 3-5. https://doi.org/10.1007/s12154-012-0088-8
Domart, Marie-Charlotte, and Larijani, Banafshé. "Lipid-dependent and -independent regulation of nuclear envelope disassembly." Journal of chemical biology vol. 6,1 (2012): 3-5. doi: https://doi.org/10.1007/s12154-012-0088-8
Domart MC, Larijani B. Lipid-dependent and -independent regulation of nuclear envelope disassembly. J Chem Biol. 2012 Dec 18;6(1):3-5. doi: 10.1007/s12154-012-0088-8. eCollection 2012. PMID: 24348875; PMCID: PMC3536866.
Copy Download .nbib Format: NLM
Diastereoselective alkylation of 2,3,4,6-Di-O-isopropylidene-2-keto-L-gulonic amides. Application to the asymmetric synthesis of 1-substituted-1,2,3,4-tetrahydroisoquinolines and 1-substituted-1,2,3,4,-tetrahydro-beta-carbolines.

The Journal of organic chemistry

Adam S, Pannecoucke X, Combret JC, Quirion JC.
PMID: 11749602
J Org Chem. 2001 Dec 28;66(26):8744-50. doi: 10.1021/jo0155658.

The diastereoselective alkylation of amides 3a,b and 7a,b derived from gulonic acid is described. Substituted compounds are obtained in good yield and high diastereoselectivity. A mechanistic investigation establishes that the diastereoselectivity did not arise from an initial asymmetric deprotonation....

Cite
Adam S, Pannecoucke X, Combret JC, et al. Diastereoselective alkylation of 2,3,4,6-Di-O-isopropylidene-2-keto-L-gulonic amides. Application to the asymmetric synthesis of 1-substituted-1,2,3,4-tetrahydroisoquinolines and 1-substituted-1,2,3,4,-tetrahydro-beta-carbolines. J Org Chem. 2001;66(26):8744-50doi: 10.1021/jo0155658.
Adam, S., Pannecoucke, X., Combret, J. C., & Quirion, J. C. (2001). Diastereoselective alkylation of 2,3,4,6-Di-O-isopropylidene-2-keto-L-gulonic amides. Application to the asymmetric synthesis of 1-substituted-1,2,3,4-tetrahydroisoquinolines and 1-substituted-1,2,3,4,-tetrahydro-beta-carbolines. The Journal of organic chemistry, 66(26), 8744-50. https://doi.org/10.1021/jo0155658
Adam, S, et al. "Diastereoselective alkylation of 2,3,4,6-Di-O-isopropylidene-2-keto-L-gulonic amides. Application to the asymmetric synthesis of 1-substituted-1,2,3,4-tetrahydroisoquinolines and 1-substituted-1,2,3,4,-tetrahydro-beta-carbolines." The Journal of organic chemistry vol. 66,26 (2001): 8744-50. doi: https://doi.org/10.1021/jo0155658
Adam S, Pannecoucke X, Combret JC, Quirion JC. Diastereoselective alkylation of 2,3,4,6-Di-O-isopropylidene-2-keto-L-gulonic amides. Application to the asymmetric synthesis of 1-substituted-1,2,3,4-tetrahydroisoquinolines and 1-substituted-1,2,3,4,-tetrahydro-beta-carbolines. J Org Chem. 2001 Dec 28;66(26):8744-50. doi: 10.1021/jo0155658. PMID: 11749602.
Copy Download .nbib Format: NLM
Monoclonal Anti-TNF-α Antibodies for Severe Steroid-Dependent Asthma: A Case Series.

The open respiratory medicine journal

Taillé C, Poulet C, Marchand-Adam S, Borie R, Dombret MC, Crestani B, Aubier M.
PMID: 23526476
Open Respir Med J. 2013;7:21-5. doi: 10.2174/1874306401307010021. Epub 2013 Feb 22.

BACKGROUND: Refractory asthma represents an important condition, with considerable morbidity and mortality. Tumor necrosis factor α (TNF-α) is a potential target for treatment of severe asthma. However, controlled studies have shown controversial results and the risk-benefit profile of TNF-blocking...

Cite
Taillé C, Poulet C, Marchand-Adam S, et al. Monoclonal Anti-TNF-α Antibodies for Severe Steroid-Dependent Asthma: A Case Series. Open Respir Med J. 2013;7:21-5doi: 10.2174/1874306401307010021.
Taillé, C., Poulet, C., Marchand-Adam, S., Borie, R., Dombret, M. C., Crestani, B., & Aubier, M. (2013). Monoclonal Anti-TNF-α Antibodies for Severe Steroid-Dependent Asthma: A Case Series. The open respiratory medicine journal, 721-5. https://doi.org/10.2174/1874306401307010021
Taillé, Camille, et al. "Monoclonal Anti-TNF-α Antibodies for Severe Steroid-Dependent Asthma: A Case Series." The open respiratory medicine journal vol. 7 (2013): 21-5. doi: https://doi.org/10.2174/1874306401307010021
Taillé C, Poulet C, Marchand-Adam S, Borie R, Dombret MC, Crestani B, Aubier M. Monoclonal Anti-TNF-α Antibodies for Severe Steroid-Dependent Asthma: A Case Series. Open Respir Med J. 2013;7:21-5. doi: 10.2174/1874306401307010021. Epub 2013 Feb 22. PMID: 23526476; PMCID: PMC3601337.
Copy Download .nbib Format: NLM
SNP-array lesions in core binding factor acute myeloid leukemia.

Oncotarget

Duployez N, Boudry-Labis E, Roumier C, Boissel N, Petit A, Geffroy S, Helevaut N, Celli-Lebras K, Terré C, Fenneteau O, Cuccuini W, Luquet I, Lapillonne H, Lacombe C, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C.
PMID: 29464086
Oncotarget. 2018 Jan 08;9(5):6478-6489. doi: 10.18632/oncotarget.24031. eCollection 2018 Jan 19.

Acute myeloid leukemia (AML) with t(8;21) and inv(16), together referred as core binding factor (CBF)-AML, are recognized as unique entities. Both rearrangements share a common pathophysiology, the disruption of the CBF, and a relatively good prognosis. Experiments have demonstrated...

Cite
Duployez N, Boudry-Labis E, Roumier C, et al. SNP-array lesions in core binding factor acute myeloid leukemia. Oncotarget. 2018;9(5):6478-6489doi: 10.18632/oncotarget.24031.
Duployez, N., Boudry-Labis, E., Roumier, C., Boissel, N., Petit, A., Geffroy, S., Helevaut, N., Celli-Lebras, K., Terré, C., Fenneteau, O., Cuccuini, W., Luquet, I., Lapillonne, H., Lacombe, C., Cornillet, P., Ifrah, N., Dombret, H., Leverger, G., Jourdan, E., & Preudhomme, C. (2018). SNP-array lesions in core binding factor acute myeloid leukemia. Oncotarget, 9(5), 6478-6489. https://doi.org/10.18632/oncotarget.24031
Duployez, Nicolas, et al. "SNP-array lesions in core binding factor acute myeloid leukemia." Oncotarget vol. 9,5 (2018): 6478-6489. doi: https://doi.org/10.18632/oncotarget.24031
Duployez N, Boudry-Labis E, Roumier C, Boissel N, Petit A, Geffroy S, Helevaut N, Celli-Lebras K, Terré C, Fenneteau O, Cuccuini W, Luquet I, Lapillonne H, Lacombe C, Cornillet P, Ifrah N, Dombret H, Leverger G, Jourdan E, Preudhomme C. SNP-array lesions in core binding factor acute myeloid leukemia. Oncotarget. 2018 Jan 08;9(5):6478-6489. doi: 10.18632/oncotarget.24031. eCollection 2018 Jan 19. PMID: 29464086; PMCID: PMC5814226.
Copy Download .nbib Format: NLM
Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status.

Blood

Roboz GJ, Ravandi F, Wei AH, Dombret H, Thol F, Voso MT, Schuh AC, Porkka K, La Torre I, Skikne BS, Zhong J, Beach CL, Risueño A, Lopes de Menezes D, Ossenkoppele GJ, Döhner H.
PMID: 34995344
Blood. 2022 Jan 07; doi: 10.1182/blood.2021013404. Epub 2022 Jan 07.

Measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy is predictive of early relapse and poor survival. Post-remission maintenance therapy that prolongs MRD negativity or converts MRD positive (MRD+) patients to MRD...

Cite
Roboz GJ, Ravandi F, Wei AH, et al. Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status. Blood. 2022;doi: 10.1182/blood.2021013404.
Roboz, G. J., Ravandi, F., Wei, A. H., Dombret, H., Thol, F., Voso, M. T., Schuh, A. C., Porkka, K., La Torre, I., Skikne, B. S., Zhong, J., Beach, C. L., Risueño, A., Lopes de Menezes, D., Ossenkoppele, G. J., & Döhner, H. (2022). Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status. Blood, . https://doi.org/10.1182/blood.2021013404
Roboz, Gail J, et al. "Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status." Blood vol. (2022). doi: https://doi.org/10.1182/blood.2021013404
Roboz GJ, Ravandi F, Wei AH, Dombret H, Thol F, Voso MT, Schuh AC, Porkka K, La Torre I, Skikne BS, Zhong J, Beach CL, Risueño A, Lopes de Menezes D, Ossenkoppele GJ, Döhner H. Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status. Blood. 2022 Jan 07; doi: 10.1182/blood.2021013404. Epub 2022 Jan 07. PMID: 34995344.
Copy Download .nbib Format: NLM
Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial.

JAMA network open

Dinh A, Duran C, Ropers J, Bouchand F, Davido B, Deconinck L, Matt M, Senard O, Lagrange A, Mellon G, Calin R, Makhloufi S, de Lastours V, Mathieu E, Kahn JE, Rouveix E, Grenet J, Dumoulin J, Chinet T, Pépin M, Delcey V, Diamantis S, Benhamou D, Vitrat V, Dombret MC, Guillemot D, Renaud B, Claessens YE, Labarère J, Aegerter P, Bedos JP, Crémieux AC.
PMID: 34652445
JAMA Netw Open. 2021 Oct 01;4(10):e2129566. doi: 10.1001/jamanetworkopen.2021.29566.

IMPORTANCE: Failure of treatment is the most serious complication in community-acquired pneumonia (CAP).OBJECTIVE: To assess the potential risk factors for treatment failure in clinically stable patients with CAP.DESIGN, SETTING, AND PARTICIPANTS: This secondary analysis assesses data from a randomized...

Cite
Dinh A, Duran C, Ropers J, et al. Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2021;4(10):e2129566doi: 10.1001/jamanetworkopen.2021.29566.
Dinh, A., Duran, C., Ropers, J., Bouchand, F., Davido, B., Deconinck, L., Matt, M., Senard, O., Lagrange, A., Mellon, G., Calin, R., Makhloufi, S., de Lastours, V., Mathieu, E., Kahn, J. E., Rouveix, E., Grenet, J., Dumoulin, J., Chinet, T., Pépin, M., Delcey, V., Diamantis, S., Benhamou, D., Vitrat, V., Dombret, M. C., Guillemot, D., Renaud, B., Claessens, Y. E., Labarère, J., Aegerter, P., Bedos, J. P., Crémieux, A. C. (2021). Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial. JAMA network open, 4(10), e2129566. https://doi.org/10.1001/jamanetworkopen.2021.29566
Dinh, Aurélien, et al. "Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial." JAMA network open vol. 4,10 (2021): e2129566. doi: https://doi.org/10.1001/jamanetworkopen.2021.29566
Dinh A, Duran C, Ropers J, Bouchand F, Davido B, Deconinck L, Matt M, Senard O, Lagrange A, Mellon G, Calin R, Makhloufi S, de Lastours V, Mathieu E, Kahn JE, Rouveix E, Grenet J, Dumoulin J, Chinet T, Pépin M, Delcey V, Diamantis S, Benhamou D, Vitrat V, Dombret MC, Guillemot D, Renaud B, Claessens YE, Labarère J, Aegerter P, Bedos JP, Crémieux AC. Factors Associated With Treatment Failure in Moderately Severe Community-Acquired Pneumonia: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2021 Oct 01;4(10):e2129566. doi: 10.1001/jamanetworkopen.2021.29566. PMID: 34652445; PMCID: PMC8520128.
Copy Download .nbib Format: NLM
Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.

Haematologica

Roboz GJ, Döhner H, Pocock C, Dombret H, Ravandi F, Jang JH, Selleslag D, Mayer J, Martens UM, Liesveld J, Bernal T, Wang MC, Yu P, Shi L, Guo S, La Torre I, Skikne B, Dong Q, Braverman J, Nehme SA, Beach CL, Wei AH.
PMID: 34551506
Haematologica. 2021 Dec 01;106(12):3240-3244. doi: 10.3324/haematol.2021.279174.

No abstract available.

Cite
Roboz GJ, Döhner H, Pocock C, et al. Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. Haematologica. 2021;106(12):3240-3244doi: 10.3324/haematol.2021.279174.
Roboz, G. J., Döhner, H., Pocock, C., Dombret, H., Ravandi, F., Jang, J. H., Selleslag, D., Mayer, J., Martens, U. M., Liesveld, J., Bernal, T., Wang, M. C., Yu, P., Shi, L., Guo, S., La Torre, I., Skikne, B., Dong, Q., Braverman, J., Nehme, S. A., Beach, C. L., & Wei, A. H. (2021). Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. Haematologica, 106(12), 3240-3244. https://doi.org/10.3324/haematol.2021.279174
Roboz, Gail J, et al. "Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial." Haematologica vol. 106,12 (2021): 3240-3244. doi: https://doi.org/10.3324/haematol.2021.279174
Roboz GJ, Döhner H, Pocock C, Dombret H, Ravandi F, Jang JH, Selleslag D, Mayer J, Martens UM, Liesveld J, Bernal T, Wang MC, Yu P, Shi L, Guo S, La Torre I, Skikne B, Dong Q, Braverman J, Nehme SA, Beach CL, Wei AH. Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. Haematologica. 2021 Dec 01;106(12):3240-3244. doi: 10.3324/haematol.2021.279174. PMID: 34551506; PMCID: PMC8634169.
Copy Download .nbib Format: NLM
Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Respiratory medicine

Naccache JM, Jouneau S, Didier M, Borie R, Cachanado M, Bourdin A, Reynaud-Gaubert M, Bonniaud P, Israël-Biet D, Prévot G, Hirschi S, Lebargy F, Marchand-Adam S, Bautin N, Traclet J, Gomez E, Leroy S, Gagnadoux F, Rivière F, Bergot E, Gondouin A, Blanchard E, Parrot A, Blanc FX, Chabrol A, Dominique S, Gibelin A, Tazi A, Berard L, Brillet PY, Debray MP, Rousseau A, Kerjouan M, Freynet O, Dombret MC, Gamez AS, Nieves A, Beltramo G, Pastré J, Le Borgne-Krams A, Dégot T, Launois C, Plantier L, Wémeau-Stervinou L, Cadranel J, Chenivesse C, Valeyre D, Crestani B, Cottin V, Simon T, Nunes H.
PMID: 34506761
Lancet Respir Med. 2021 Sep 07; doi: 10.1016/S2213-2600(21)00354-4. Epub 2021 Sep 07.

BACKGROUND: The use of cyclophosphamide in patients with acute exacerbation of idiopathic pulmonary fibrosis (IPF) is unknown. Our study was designed to evaluate the efficacy and safety of four cyclophosphamide pulses in addition to high-dose methylprednisolone in this population.METHODS:...

Cite
Naccache JM, Jouneau S, Didier M, et al. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021;doi: 10.1016/S2213-2600(21)00354-4.
Naccache, J. M., Jouneau, S., Didier, M., Borie, R., Cachanado, M., Bourdin, A., Reynaud-Gaubert, M., Bonniaud, P., Israël-Biet, D., Prévot, G., Hirschi, S., Lebargy, F., Marchand-Adam, S., Bautin, N., Traclet, J., Gomez, E., Leroy, S., Gagnadoux, F., Rivière, F., Bergot, E., Gondouin, A., Blanchard, E., Parrot, A., Blanc, F. X., Chabrol, A., Dominique, S., Gibelin, A., Tazi, A., Berard, L., Brillet, P. Y., Debray, M. P., Rousseau, A., Kerjouan, M., Freynet, O., Dombret, M. C., Gamez, A. S., Nieves, A., Beltramo, G., Pastré, J., Le Borgne-Krams, A., Dégot, T., Launois, C., Plantier, L., Wémeau-Stervinou, L., Cadranel, J., Chenivesse, C., Valeyre, D., Crestani, B., Cottin, V., Simon, T., Nunes, H. (2021). Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Respiratory medicine, . https://doi.org/10.1016/S2213-2600(21)00354-4
Naccache, Jean-Marc, et al. "Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial." The Lancet. Respiratory medicine vol. (2021). doi: https://doi.org/10.1016/S2213-2600(21)00354-4
Naccache JM, Jouneau S, Didier M, Borie R, Cachanado M, Bourdin A, Reynaud-Gaubert M, Bonniaud P, Israël-Biet D, Prévot G, Hirschi S, Lebargy F, Marchand-Adam S, Bautin N, Traclet J, Gomez E, Leroy S, Gagnadoux F, Rivière F, Bergot E, Gondouin A, Blanchard E, Parrot A, Blanc FX, Chabrol A, Dominique S, Gibelin A, Tazi A, Berard L, Brillet PY, Debray MP, Rousseau A, Kerjouan M, Freynet O, Dombret MC, Gamez AS, Nieves A, Beltramo G, Pastré J, Le Borgne-Krams A, Dégot T, Launois C, Plantier L, Wémeau-Stervinou L, Cadranel J, Chenivesse C, Valeyre D, Crestani B, Cottin V, Simon T, Nunes H. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021 Sep 07; doi: 10.1016/S2213-2600(21)00354-4. Epub 2021 Sep 07. PMID: 34506761.
Copy Download .nbib Format: NLM
Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy.

Blood

Itzykson R, Fournier E, Berthon C, Röllig C, Braun T, Marceau-Renaut A, Pautas C, Nibourel O, Lemasle E, Micol JB, Adès L, Lebon D, Malfuson JV, Gastaud L, Goursaud L, Raffoux E, Wattebled KJ, Rousselot P, Thomas X, Chantepie S, Cluzeau T, Serve H, Boissel N, Terré C, Celli-Lebras K, Preudhomme C, Thiede C, Dombret H, Gardin C, Duployez N.
PMID: 34410352
Blood. 2021 Aug 19;138(7):507-519. doi: 10.1182/blood.2021011103.

To design a simple and reproducible classifier predicting the overall survival (OS) of patients with acute myeloid leukemia (AML) ≥60 years of age treated with 7 + 3, we sequenced 37 genes in 471 patients from the ALFA1200 (Acute...

Cite
Itzykson R, Fournier E, Berthon C, et al. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021;138(7):507-519doi: 10.1182/blood.2021011103.
Itzykson, R., Fournier, E., Berthon, C., Röllig, C., Braun, T., Marceau-Renaut, A., Pautas, C., Nibourel, O., Lemasle, E., Micol, J. B., Adès, L., Lebon, D., Malfuson, J. V., Gastaud, L., Goursaud, L., Raffoux, E., Wattebled, K. J., Rousselot, P., Thomas, X., Chantepie, S., Cluzeau, T., Serve, H., Boissel, N., Terré, C., Celli-Lebras, K., Preudhomme, C., Thiede, C., Dombret, H., Gardin, C., & Duployez, N. (2021). Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood, 138(7), 507-519. https://doi.org/10.1182/blood.2021011103
Itzykson, Raphael, et al. "Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy." Blood vol. 138,7 (2021): 507-519. doi: https://doi.org/10.1182/blood.2021011103
Itzykson R, Fournier E, Berthon C, Röllig C, Braun T, Marceau-Renaut A, Pautas C, Nibourel O, Lemasle E, Micol JB, Adès L, Lebon D, Malfuson JV, Gastaud L, Goursaud L, Raffoux E, Wattebled KJ, Rousselot P, Thomas X, Chantepie S, Cluzeau T, Serve H, Boissel N, Terré C, Celli-Lebras K, Preudhomme C, Thiede C, Dombret H, Gardin C, Duployez N. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood. 2021 Aug 19;138(7):507-519. doi: 10.1182/blood.2021011103. PMID: 34410352.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 43 entries